Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ilari Lehtinen"'
Autor:
Miikka Lehtonen, Jorma Sormunen, Tiina Luukkaala, Timo Marttila, Ray McDermott, Timo Joensuu, Ilari Lehtinen, Claes Ginman, Pirkko-Liisa Kellokumpu-Lehtinen
Introduction: Treatment with 2-weekly docetaxel 50 mg/m2 was shown to improve overall survival and was better tolerated than the standard 75 mg/m2 3-weekly regimen in men with metastatic castration-resistant prostate cancer (mCRPC) in the original ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::122cbeb4f20ed8b0403fb5ff04a84700
https://trepo.tuni.fi/handle/10024/141440
https://trepo.tuni.fi/handle/10024/141440
Autor:
Ilari Lehtinen, Pekka Taimen, Ilkka Nikulainen, Peter J. Boström, Otto Ettala, Johanna Schleutker, Elina Kaikkonen, Pirkko-Liisa Kellokumpu-Lehtinen
Publikováno v:
Anticancer Research. 39:5353-5359
Background Identification of genetic prognostic biomarkers, such as germline variants, are urgently needed to choose optimal treatment for metastatic castration-resistant prostate cancer (mCRPC). Patients and methods The prognostic value of anoctamin
Autor:
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Ilari Lehtinen, Johanna Sjöström-Mattson, Kaisa L. Sunela
Publikováno v:
Clinical Breast Cancer. 7:401-405
Few overlapping toxicities and oral formulations make capecitabine plus oral vinorelbine an attractive new combination for treating patients with breast cancer. An all-oral regimen minimizes inconvenience for the patient and saves medical resources.
Autor:
Pirkko-Liiisa, Kellokumpu-Lehtinen, Tuija, Tuunanen, Anna-Liisa, Kautio, Ilari, Lehtinen, Minna, Tanner
Publikováno v:
Anticancer research. 33(11)
Chemotherapy given every third week is currently the mainstay in the treatment of metastatic breast cancer (MBC). However, bi-weekly dosing might offer a better dose intensity, with better tolerability and response rates. This hypothesis was tested i
Autor:
Pirkko, Kellokumpu-Lehtinen, Tuija, Tuunanen, Raija, Asola, Liisa, Elomaa, Mirja, Heikkinen, Riitta, Kokko, Ritva, Järvenpää, Ilari, Lehtinen, Abdel, Maiche, Jaana, Kaleva-Kerola, Mauri, Huusko, Kari, Möykkynen, Timo, Ala-Luhtala
Publikováno v:
Anticancer research. 33(6)
Weekly paclitaxel is widely used in the treatment of metastatic breast cancer (MBC). Our aim was to test its efficacy and tolerability as a second-line therapy for MBC in daily oncology practice.Paclitaxel (90 mg/m(2)) was given intravenously three t
Autor:
Markku J Leskinen, Marjaana Luukkaa, Petteri Hervonen, Katariina Klintrup, Ilari Lehtinen, Tapio Utriainen, Kalevi Pulkkanen, Anna-Liisa Kautio, Mikko Taalikka, Antti Jekunen, Timo Marttila, Pirkko-Liisa Kellokumpu-Lehtinen, Vesa Kataja
Publikováno v:
Journal of Clinical Oncology. 34:e16523-e16523
e16523Background: In our Prosty I trial biweekly docetaxel (D) was better tolerated and yielded longer overall survival than standard triweekly D (Kellokumpu-Lehtinen et al. Lancet Oncol 2013;14:11...
Autor:
Pirkko-Liisa Kellokumpu-Lehtinen, Katinka Sandberg, Tiina Luukkaala, Claes Ginman, Ulrika Harmenberg, Ilari Lehtinen, Raymond S. McDermott, Raija Asola, Petteri Hervonen, Sten Nilsson, John McCaffrey, Akseli Hemminki, Marjaana Luukkaa, Taina Turpeenniemi Hujanen, Timo Joensuu, Paul Nyandoto, Heikki Joensuu, Maccon M. Keane, Tiina Tasmuth, Fredrik Laestadius
Publikováno v:
Journal of Clinical Oncology. 32:23-23
23 Background: Bi-weekly docetaxel (T) with prednisone improved progression free survival and overall survival when compared with the standard tri-weekly T as first-line treatment for advanced castration resistant prostate cancer (CRPC) (Lancet Oncol
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.